There had been several studies relating to the automated defibrillator and cost-effectiveness of it. The Multi-center Automated Defibrillator Implantation Trial (MADIT) took up a study to decide the same. The study showed improved survival in selected asymptomatic patients with coronary disease and un-sustained ventricular tachycardia. To decide the cost-effectiveness of the automated defibrillator the patients were regularly followed up and their use of healthcare services was taken in to account. These included visits to hospitals or physicians, laboratory tests procedures, medications etc. To decide the cost-effectiveness the study was randomized against the use of defibrillators and other conventional medical treatments....
Medtronic is the manufacturer of the LIFEPAK 2 defibrillator used by mobile emergency responders and hospitals alike. The LIFEPAK 2 has many unique life saving features that distinguishes it from other defibrillators. The versatility of the defibrillator makes it one of the most popular with nearly one half million purchased worldwide.
Atrial Fibrillation can be acute and life-threatening, paroxysmal (intermittent), or chronic, and its symptoms can range in severity from mild lethargy to stroke.
Sudden cardiac death (sudden arrest) is death resulting from a sudden heart attack (cardiac arrest). The victim may or may not have diagnosed heart disease. The time and mode of death are unexpected.